Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular imaging and molecular diagnostics: two sides of the same coin?

Molecular imaging and molecular diagnostics: two sides of the same coin? European Journal of Nuclear Medicine and Molecular Imaging (2018) 45:1645–1648 https://doi.org/10.1007/s00259-018-4060-x EDITORIAL Molecular imaging and molecular diagnostics: two sides of the same coin? 1,2 3,4 2,5,6,7 Marcus Hacker & Gregor Hoermann & Lukas Kenner Published online: 2 June 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 Back in the 1950s, it was a common concept to start further radioimmunoassays were developed for the analysis and in- education in internal medicine with pathology [1]. The idea terpretation of thyroid hormone constellations in the blood, a behind this was that a deeper knowledge of anatomy and comprehensive theranostic approach which finally led to pre- pathohistomorphology of diseases would improve the accura- cise treatment with thyroid hormones and radioiodine. Given cy of diagnosis and the success of treatment. It was during this this historical development and the partly overlapping tech- period when internal medicine specialists started to utilize niques applied, it is surprising that the obvious synergisms radioactive isotopes as tracers in biological assays, in vitro among nuclear medicine, pathology and laboratory medicine, to enhance their understanding of molecular processes and which in many countries today is fused with clinical chemis- in vivo to improve diagnostics – never losing sight of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Nuclear Medicine and Molecular Imaging Springer Journals

Molecular imaging and molecular diagnostics: two sides of the same coin?

Download PDF
4 pages

Loading next page...
 
/lp/springer_journal/molecular-imaging-and-molecular-diagnostics-two-sides-of-the-same-coin-gaNf5yvCrG
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1619-7070
eISSN
1619-7089
DOI
10.1007/s00259-018-4060-x
pmid
29860534
Publisher site
See Article on Publisher Site

Abstract

European Journal of Nuclear Medicine and Molecular Imaging (2018) 45:1645–1648 https://doi.org/10.1007/s00259-018-4060-x EDITORIAL Molecular imaging and molecular diagnostics: two sides of the same coin? 1,2 3,4 2,5,6,7 Marcus Hacker & Gregor Hoermann & Lukas Kenner Published online: 2 June 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 Back in the 1950s, it was a common concept to start further radioimmunoassays were developed for the analysis and in- education in internal medicine with pathology [1]. The idea terpretation of thyroid hormone constellations in the blood, a behind this was that a deeper knowledge of anatomy and comprehensive theranostic approach which finally led to pre- pathohistomorphology of diseases would improve the accura- cise treatment with thyroid hormones and radioiodine. Given cy of diagnosis and the success of treatment. It was during this this historical development and the partly overlapping tech- period when internal medicine specialists started to utilize niques applied, it is surprising that the obvious synergisms radioactive isotopes as tracers in biological assays, in vitro among nuclear medicine, pathology and laboratory medicine, to enhance their understanding of molecular processes and which in many countries today is fused with clinical chemis- in vivo to improve diagnostics – never losing sight of

Journal

European Journal of Nuclear Medicine and Molecular Imaging – Springer Journals

Published: Jun 2, 2018

References

  • Individualized medicine from prewomb to tomb
    Topol, EJ
  • Lung cancer
    Herbst, RS; Heymach, JV; Lippman, SM
  • Role of randomized phase III trials in an era of effective targeted therapies
    Sharma, MR; Schilsky, RL
  • Clinical development success rates for investigational drugs
    Hay, M; Thomas, DW; Craighead, JL; Economides, C; Rosenthal, J
  • Tumour heterogeneity and resistance to cancer therapies
    Dagogo-Jack, I; Shaw, AT
  • The hallmarks of cancer
    Hanahan, D; Weinberg, RA
  • Hallmarks of cancer: the next generation
    Hanahan, D; Weinberg, RA
  • Liquid biopsies come of age: towards implementation of circulating tumour DNA
    Wan, JCM; Massie, C; Garcia-Corbacho, J; Mouliere, F; Brenton, JD; Caldas, C
  • Detection and localization of surgically resectable cancers with a multi-analyte blood test
    Cohen, JD; Li, L; Wang, Y; Thoburn, C; Afsari, B; Danilova, L
  • 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients
    Gaykema, SB; Schroder, CP; Vitfell-Rasmussen, J; Chua, S; Oude Munnink, TH; Brouwers, AH
  • PET imaging of oestrogen receptors in patients with breast cancer
    Kruchten, M; Vries, EGE; Brown, M; Vries, EFJ; Glaudemans, AWJM; Dierckx, RAJO
  • Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study
    Meng, X; Loo, BW; Ma, L; Murphy, JD; Sun, X; Yu, J
  • A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management
    Sun, X; Xiao, Z; Chen, G; Han, Z; Liu, Y; Zhang, C
  • Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors
    Strosberg, J; El-Haddad, G; Wolin, E; Hendifar, A; Yao, J; Chasen, B
  • (177)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
    Yadav, MP; Ballal, S; Tripathi, M; Damle, NA; Sahoo, RK; Seth, A
  • Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy
    Eiber, M; Maurer, T; Souvatzoglou, M; Beer, AJ; Ruffani, A; Haller, B
  • Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers
    Jiang, R; Dong, X; Zhu, W; Duan, Q; Xue, Y; Shen, Y
  • Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients
    Winther-Larsen, A; Demuth, C; Fledelius, J; Madsen, AT; Hjorthaug, K; Meldgaard, P
  • Early change in FDG-PET signal and plasma cell-free DNA level predicts erlotinib response in EGFR wild-type NSCLC patients
    Winther-Larsen, A; Fledelius, J; Demuth, C; Bylov, CM; Meldgaard, P; Sorensen, BS